Cargando…
Optimized GIP analogs promote body weight lowering in mice through GIPR agonism not antagonism
OBJECTIVE: Structurally-improved GIP analogs were developed to determine precisely whether GIP receptor (GIPR) agonism or antagonism lowers body weight in obese mice. METHODS: A series of peptide-based GIP analogs, including structurally diverse agonists and a long-acting antagonist, were generated...
Autores principales: | Mroz, Piotr A., Finan, Brian, Gelfanov, Vasily, Yang, Bin, Tschöp, Matthias H., DiMarchi, Richard D., Perez-Tilve, Diego |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6358549/ https://www.ncbi.nlm.nih.gov/pubmed/30578168 http://dx.doi.org/10.1016/j.molmet.2018.12.001 |
Ejemplares similares
-
GIP receptor agonism improves dyslipidemia and atherosclerosis independently of body weight loss in preclinical mouse model for cardio-metabolic disease
por: Sachs, Stephan, et al.
Publicado: (2023) -
The glucose-dependent insulinotropic polypeptide (GIP) regulates body weight and food intake via CNS-GIPR signaling
por: Zhang, Qian, et al.
Publicado: (2021) -
Targeting the GIPR for obesity: To agonize or antagonize? Potential mechanisms
por: Campbell, Jonathan E.
Publicado: (2020) -
Chronic glucose-dependent insulinotropic polypeptide receptor (GIPR) agonism desensitizes adipocyte GIPR activity mimicking functional GIPR antagonism
por: Killion, Elizabeth A., et al.
Publicado: (2020) -
“Let's Stay Together”; GIP and GLP-1 dual agonism in the treatment of metabolic disease
por: DiMarchi, Richard D.
Publicado: (2018)